Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics

被引:1
|
作者
Cao, Huijun [1 ]
Shangguan, Linjue [2 ]
Zhu, Hanlin [3 ]
Hu, Chunfeng [1 ]
Zhang, Tong [1 ]
Han, Zhijiang [4 ]
Wei, Peiying [4 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Clin Med 4, Hangzhou 310053, Peoples R China
[2] Hangzhou Canc Hosp, Hangzhou 310005, Peoples R China
[3] Hangzhou Ninth Peoples Hosp, Dept Radiol, Hangzhou 310012, Peoples R China
[4] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, 261 Huansha Rd, Hangzhou 310006, Peoples R China
关键词
papillary thyroid carcinoma; Iodine-131; radiomics; predictive model; treatment outcome; STIMULATED THYROGLOBULIN LEVEL; CANCER; IMPACT; TOMOGRAPHY; ABLATION;
D O I
10.1210/clinem/dgae364
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To develop and validate a radiomics-clinical combined model combining preoperative computed tomography (CT) and clinical data from patients with papillary thyroid carcinoma (PTC) to predict the efficacy of initial postoperative I-131 treatment. Methods: A total of 181 patients with PTC who received total thyroidectomy and initial I-131 treatment were divided into training and testing sets (7:3 ratio). Univariate analysis and multivariate logistic regression were used to screen clinical factors affecting the therapeutic response to I-131 treatment and construct a clinical model. Radiomics features extracted from preoperative CT images of PTCs were dimensionally reduced through recursive feature elimination and least absolute shrinkage and selection operator. Logistic regression was used to establish a radiomics model, and a radiomics-clinical combined model was developed by integrating the clinical model. The area under the curve (AUC), sensitivity, and specificity were used to evaluate the prediction performance of each model. Results: Multivariate analysis revealed that pre-I-131 treatment serum thyroglobulin was an independent clinical risk factor affecting the efficacy of initial I-131 treatment (P = .002), and the AUC, sensitivity, and specificity for predicting the efficacy of initial I-131 treatment were 0.895, 0.899, and 0.816, respectively. After dimensionality reduction, 14 key CT radiomics features of PTCs were included. The established radiomics model predicted the efficacy of I-131 treatment in the training and testing sets with AUCs of 0.825 and 0.809, sensitivities of 0.828 and 0.636, and specificities of 0.745 and 0.944, respectively. The combined model improved the AUC, sensitivity, and specificity in both sets. Conclusion: The preoperative CT-based radiomics model can effectively predict the efficacy of initial postoperative I-131 treatment in patients with intermediate- or high-risk PTC, and the radiomics-clinical combined model exhibits better predictive performance.
引用
收藏
页码:3036 / 3045
页数:10
相关论文
共 50 条
  • [21] Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma
    Verburg, Frederik A.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (03) : 253 - 257
  • [22] The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis
    Dominguez-Ayala, Maite
    Minguez-Gabina, Pablo
    Paja-fano, Miguel
    Bilbao-gonzalez, Amaia
    Exposito-rodriguez, Amaia
    Rodeno-Ortiz de Zarate, Emilia
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 67 (01) : 83 - 92
  • [23] 124I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT/CT
    de Pont, Cecile
    Halders, Servais
    Bucerius, Jan
    Mottaghy, Felix
    Brans, Boudewijn
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (05) : 693 - 700
  • [24] Sustained and Diffuse 131I Avid Bone Metastases With Low Thyroglobulin Levels in a Patient With Papillary Thyroid Carcinoma
    Zhao, Chun-Lei
    Qiu, Zhong-Ling
    Chen, Li-Bo
    Yuan, Zhi-Bin
    Luo, Quan-Yong
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (05) : 375 - 377
  • [25] The diagnostic incremental value of 131I SPECT-CT scan compared to planar 131I WBS for differentiated thyroid carcinoma: A single institutional experience
    Alkhybari, Essam M.
    Albeshan, Salman M.
    Alanazi, Bander M.
    Alqahtani, Dalal M.
    Abokhater, Hala K.
    Albakhiti, Sundus H.
    Ghanem, Intidhar E.
    JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES, 2021, 14 (01) : 440 - 448
  • [26] Contrast-Enhanced CT-Based Radiomics for the Differentiation of Nodular Goiter from Papillary Thyroid Carcinoma in Thyroid Nodules
    Li, Zhenyu
    Zhang, Haiming
    Chen, Wenying
    Li, Hengguo
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1131 - 1140
  • [27] Changes of Regulatory T and B Cells in Patients with Papillary Thyroid Carcinoma after 131I Radioablation: A Preliminary Study
    Jiang, Lei
    Zhan, Yanxia
    Gu, Yusen
    Ye, Yi
    Cheng, Yunfeng
    Shi, Hongcheng
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [28] Recombinant Human TSH for Thyroid Remnant Ablation with 131I in Children and Adolescents with Papillary Carcinoma
    Rosario, Pedro Weslley
    Campos Mineiro Filho, Augusto Flavio
    Lacerda, Rafaela Xavier
    Calsolari, Maria Regina
    HORMONE RESEARCH IN PAEDIATRICS, 2012, 77 (01): : 59 - 62
  • [29] Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan
    Chung, JK
    So, Y
    Lee, JS
    Choi, CW
    Lim, SM
    Lee, DS
    Hong, SW
    Youn, YK
    Lee, MC
    Cho, BY
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (06) : 986 - 992
  • [30] Role of Diagnostic 131I SPECT/CT in Long-Term Follow-up of Patients with Papillary Thyroid Microcarcinoma
    Spanu, Angela
    Nuvoli, Susanna
    Gelo, Ilaria
    Mele, Luciana
    Piras, Bastiana
    Madeddu, Giuseppe
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (10) : 1510 - 1515